Breast Cancer MCF-7 Cell Spheroid Culture for Drug Discovery and Development
Overview
Authors
Affiliations
3D cancer spheroids (tumoroids) exhibit a drug resistance profile similar to that found in solid tumors. 3D spheroid culture methods recreate more physiologically relevant microenvironments for cells. Therefore, these models are more appropriate for cancer drug screening. We have recently developed a protocol for MCF-7 cell spheroid culture, and used this method to test the effects of different types of drugs on this estrogen-dependent breast cancer cell spheroid. Our results demonstrated that MCF-7 cells can grow spheroid in medium using a low attachment plate. We managed to grow one spheroid in each well, and the spheroid can grow over a month, the size of the spheroid can grow over a hundred times in volume. Our targeted drug experimental results suggest that estrogen sulfotransferase, steroid sulfatase, and G protein-coupled estrogen receptor may play critical roles in MCF-7 cell spheroid growth, while estrogen receptors and may not play an essential role in MCF-7 spheroid growth. Organoids are the miniatures of tissues and reiterate the microenvironment of a specific organ, best fit for the studies of diseases and drug development. Tumoroid, developed from cancer cell lines or patients' tumor tissue, is the best model of tumors. 3D spheroid technology will be the best future method for drug development of cancers and other diseases. Our reported method can be developed clinically to develop personalized drugs when the patient's tumor tissues are used to develop a spheroid culture for drug screening.
A Brief History of Cell Culture: From Harrison to Organs-on-a-Chip.
Moro L, Guarnier L, Azevedo M, Fracasso J, Lucio M, Castro M Cells. 2025; 13(24.
PMID: 39768159 PMC: 11674496. DOI: 10.3390/cells13242068.
Effects of the MCF-7 Exhausted Medium on hADSC Behaviour.
Garroni G, Cruciani S, Serra D, Pala R, Coradduzza D, Cossu M Int J Mol Sci. 2024; 25(13).
PMID: 39000134 PMC: 11241546. DOI: 10.3390/ijms25137026.
Hamel K, Frazier T, Williams C, Duplessis T, Rowan B, Gimble J Int J Mol Sci. 2024; 25(5.
PMID: 38473978 PMC: 10931959. DOI: 10.3390/ijms25052728.
El-Sadek I, Morishita R, Mori T, Makita S, Mukherjee P, Matsusaka S Sci Rep. 2024; 14(1):3366.
PMID: 38336794 PMC: 10858208. DOI: 10.1038/s41598-024-53171-4.
Bhattacharya A, Alam K, Roy N, Kaur K, Kaity S, Ravichandiran V J Exp Clin Cancer Res. 2023; 42(1):343.
PMID: 38102637 PMC: 10724947. DOI: 10.1186/s13046-023-02926-4.